ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2992

Are Specific Vascular Symptoms in Takayasu’s Arteritis Reflective of Vascular Inflammation, Vascular Damage, or Both?

Despina Michailidou1, Joel S. Rosenblum1, Mark A. Ahlman2, Jamie Marco3 and Peter C. Grayson4, 1NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, 2Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, 3Radiology and Imaging Sciences National Institutes of Health, Bethesda, MD, 4National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity and Takayasu.s arteritis

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, October 24, 2018

Title: 6W025 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os III: Clinical Subtype & Outcome(2988–2993)

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose:

Patients with Takayasu’s arteritis (TAK) can experience symptoms due to vascular inflammation or vascular damage. The study objective was to investigate whether specific vascular symptoms are more closely associated with vascular disease activity measured by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) or vascular damage assessed by magnetic resonance angiography (MRA).

Methods:

Patients with TAK were recruited into a prospective observational cohort. Participants underwent clinical assessment and standardized imaging assessment (FDG-PET and MRA) within a 24-hour period, blinded to each other. Vascular disease activity was defined as arterial FDG uptake > liver by visual assessment. Vascular damage was defined as either stenosis, occlusion, or aneurysm in specific arterial territories on MRA. Clinical symptoms present on the day of evaluation (carotidynia; frontal headache; arm claudication) were compared to imaging findings in corresponding arterial territories. Generalized symptoms (headache; dizziness; history of CNS event defined as TIA/stroke or syncope) were studied in association with the number of affected neck vessels by MRA. Performance characteristics were calculated and the association between clinical symptoms and imaging features was assessed by Fisher’s exact test.

Results:

51 participants contributed data from 92 study visits. For FDG-PET, the sensitivity (SN) of specific clinical symptoms ranged from 16% to 33% and specificity (SP) from 74% to 98%. For MRA the SN of the same symptoms ranged from 6% to 71% and SP from 79% to 100%. Details of specific associations are shown in the Table. Carotidynia was significantly associated with carotid activity by FDG-PET (p<0.01) but not carotid damage by MRA (p=0.18). Frontal headache was significantly associated with both carotid activity by FDG-PET (p<0.01) and carotid damage by MRA (p=0.04). Arm claudication was significantly associated with subclavian damage by MRA (p<0.01) but not subclavian activity by FDG-PET (p=0.47). Headache (p=0.02) and history of CNS events (p<0.01) was significantly associated with damage to ≥2 neck arteries, and dizziness (p<0.01) was associated with damage to ≥ 3 neck arteries.

Conclusion:

Absence of clinical symptoms does not rule out vascular abnormalities by FDG-PET or MRA, but presence of symptoms is often associated with imaging abnormalities. Certain features are more closely associated with FDG-PET activity while others are more closely linked to vascular damage. Complaints of headache, dizziness, and CNS events are associated with the burden of vascular pathology in the neck arteries. These findings have direct clinical implications and may inform the development of disease activity indices in TAK.

 

Table. Association of Clinical Symptoms with Imaging Findings in Takayasu’s Arteritis

 

Symptom

Arterial territory

Image Study

TN

TP

FN

FP

P value

Sensitivity (95% CI)

Specificity (95% CI)

Carotidynia

L carotid artery

R carotid artery

FDG-PET

122

8

17

5

<0.01

32%

(15-54%)

96%

(91-99%)

MRA

66

12

82

4

0.18

13%

(7-21%)

94%

(86-98%)

Frontal headache

L carotid artery

R carotid artery

FDG-PET

125

4

21

2

<0.01

16%

(5-36%)

98%

(94-100%)

MRA

70

6

88

0

0.04

6%

(2-13%)

100%

(95-100%)

Arm claudication

L subclavian artery

R subclavian artery

FDG-PET

95

8

16

34

0.47

33%

(16-55%)

74%

(65-81%)

MRA

67

38

49

8

<0.01

44%

(33-55%)

89%

(80-95%)

Any headache

≥2 vs <2 affected neck arteries (carotids, vertebrals)

MRA

45

12

12

12

0.02

50%

(29-71%)

79%

(66-89%)

History of CNS event

(TIA, stroke, or syncope)

≥2 vs <2 affected neck arteries (carotids, vertebrals)

MRA

45

17

7

12

<0.01

71%

(49-87%)

79%

(66-89%)

Dizziness

≥3 vs <3 affected neck arteries (carotids, vertebrals)

MRA

61

7

11

2

<0.01

39%

(17-64%)

97%

(89-100%)

TN = True Negative; TP = True Position; FN = False Negative; FP = False Position; CNS = Central Nervous System; TIA = Transient Ischemic Attack;

 


Disclosure: D. Michailidou, None; J. S. Rosenblum, None; M. A. Ahlman, None; J. Marco, None; P. C. Grayson, None.

To cite this abstract in AMA style:

Michailidou D, Rosenblum JS, Ahlman MA, Marco J, Grayson PC. Are Specific Vascular Symptoms in Takayasu’s Arteritis Reflective of Vascular Inflammation, Vascular Damage, or Both? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/are-specific-vascular-symptoms-in-takayasus-arteritis-reflective-of-vascular-inflammation-vascular-damage-or-both/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-specific-vascular-symptoms-in-takayasus-arteritis-reflective-of-vascular-inflammation-vascular-damage-or-both/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology